PAP
BBOT

Persistent Asset Partners’s BridgeBio Oncology BBOT Stock Holding History

Persistent Asset Partners’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,585
Closed -$107K – 494
2025
Q4 		$107K Buy
+8,585
New +$104K 0.05% 264

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Persistent Asset Partners's BBOT Position: Q1 2026 in Review

Persistent Asset Partners sold out of BridgeBio Oncology (BBOT) in Q1 2026, closing a stake of 8,585 shares — an estimated $107K sold.

Persistent Asset Partners first reported a position in BBOT in Q4 2025 and held it in 1 quarter. The position peaked at $107K in Q4 2025. 67 funds tracked by Wall St. Rank hold BBOT as of Q1 2026.

  • Persistent Asset Partners reported no remaining BridgeBio Oncology position as of Q1 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 8,585 BridgeBio Oncology shares in Q1 2026, an estimated $107K.
  • Persistent Asset Partners first reported a position in BridgeBio Oncology in Q4 2025 and held it in 1 quarter.
  • Persistent Asset Partners's BridgeBio Oncology position peaked at $107K in Q4 2025.
  • 67 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.